A critical review of cyclic vomiting syndrome (CVS) notes that patients commonly use cannabis for symptom relief, but cannabinoid hyperemesis syndrome (CHS) may be a subset of CVS where cannabis actually causes the vomiting.
Read this if you experience cyclic vomiting and use cannabis, or if you are a clinician managing CVS patients.
~2% prevalenceCyclic vomiting syndrome affects approximately 2% of the US population
What the researchers found
CVS affects approximately 2% of the US population with recurrent disabling episodes of nausea, vomiting, and abdominal pain. It's closely associated with migraines and likely shares pathophysiology. Patients commonly use cannabis therapeutically for symptom relief. However, cannabinoid hyperemesis syndrome (CHS) is now recognized as a potential subset of CVS where chronic heavy cannabis use leads to hyperemesis. The review recommends a biopsychosocial treatment approach with prophylactic tricyclic antidepressants, antiepileptics, or aprepitant, and abortive triptans, ondansetron, or sedation.
Why it matters
The diagnostic overlap between CVS and CHS creates a clinical challenge: cannabis may help some patients while causing symptoms in others. Clinicians need to differentiate between these scenarios for appropriate management.
The numbers in context
- CVS prevalence: ~2% in the US
- More common in females
- Associated with migraines, anxiety, depression, autonomic dysfunction
- Prophylaxis: amitriptyline, topiramate, aprepitant
- Abortive: triptans, ondansetron, sedation
How the study worked
Critical narrative review of CVS diagnosis, pathophysiology, and management, with specific attention to the cannabis-CVS-CHS relationship.
Who was studied
Patients with cyclic vomiting syndrome (general review)
What this study cannot tell us
Narrative review, not systematic. The distinction between CVS with therapeutic cannabis use and CHS remains clinically challenging. Pathophysiology of both conditions is incompletely understood.
How to read the evidence
Critical narrative review in a leading gastroenterology journal. Authoritative clinical overview.
When this study was published
Published in 2023. Reflects current understanding of the CVS-CHS diagnostic spectrum.
The bigger picture
The CVS-CHS distinction illustrates a broader pattern in cannabis medicine: the same substance can be therapeutic for some patients and pathogenic for others. Understanding who benefits and who is harmed requires better biomarkers and clinical tools.
Questions still open
- How can clinicians reliably distinguish CVS from CHS?
- Does a trial of cannabis cessation reliably differentiate the two conditions?
- Could genetic factors explain why cannabis helps some CVS patients but causes CHS in others?
Read the original research
Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.
The American journal of gastroenterology, 118(7), 1157-1167
Citation
Frazier, Rosita; Li, B U K; Venkatesan, Thangam. (2023). Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.. The American journal of gastroenterology, 118(7), 1157-1167. https://doi.org/10.14309/ajg.0000000000002216